Business Context and Reporting Period
This Form 8-K filing by Collegium Pharmaceutical, Inc. (COLL) reports the results of the Annual Meeting of Shareholders held on May 19, 2022. The record date for the meeting was March 31, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Shareholders voted on three proposals. A total of 31,262,511 shares were present in person or by proxy out of 33,923,148 shares entitled to vote.
- Proposal 1 (Election of Directors): All six nominees were re-elected to serve until the 2023 Annual Meeting.
- Rita Balice-Gordon: 28,097,111 For
- Garen Bohlin: 28,898,563 For
- John Fallon: 27,308,836 For
- John Freund: 28,580,586 For
- Neil F. McFarlane: 28,911,581 For
- Gwen Melincoff: 27,860,871 For
- Proposal 2 (Executive Compensation): Shareholders approved the compensation of named executive officers on an advisory basis with 28,337,587 votes For.
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 31,224,033 votes For.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Confirmation that all six director nominees were successfully re-elected.
- Verification of the high approval rate for the ratification of Deloitte & Touche LLP as the independent auditor.
- Review of the specific "Against" vote counts for directors John Fallon and Gwen Melincoff, which were higher than other nominees.